 0 Table of Contents |
  1 Introduction |
  2 Evidence Profiles |
  3 EvidenceVariable Profiles |
  4 Group Profiles |
  5 Citation Profiles |
  6 ArtifactAssessment Profiles |
  7 Composition Profiles |
  8 Other Profiles |
  9 Profiles |
  10 Extensions |
  11 Terminologies |
  12 Examples |
  13 Downloads |
  14 Artifacts Summary |
   14.1 Adaptation |
   14.2 BaselineMeasureEvidence |
   14.3 BaselineMeasureReport |
   14.4 BaselineVariablesList |
   14.5 BookCitation |
   14.6 BookPartCitation |
   14.7 CertaintyOfEvidence |
   14.8 Classification |
   14.9 CohortDefinition |
   14.10 Comment |
   14.11 ComparativeBaselineMeasureEvidence |
   14.12 ComparativeEvidence |
   14.13 ComparativeEvidenceReport |
   14.14 ComparativeEvidenceReportExpanded |
   14.15 ComparativeEvidenceReportSubject |
   14.16 ComparativeEvidenceSynthesisReport |
   14.17 ComparativeParticipantFlowEvidence |
   14.18 ComparatorGroup |
   14.19 ComparatorOnlyEvidence |
   14.20 Comparison |
   14.21 CompositeRating |
   14.22 ConceptualCohortDefinition |
   14.23 ConceptualComparatorDefinition |
   14.24 ConceptualExposureDefinition |
   14.25 DatabaseCitation |
   14.26 DatabaseEntryCitation |
   14.27 DatasetCitation |
   14.28 DateAsRating |
   14.29 DichotomousIntendedOutcome |
   14.30 EndpointAnalysisPlan |
   14.31 EvidenceAssessment |
   14.32 EvidenceList |
   14.33 EvidenceReport |
   14.34 EvidenceReportPackage |
   14.35 EvidenceReportSubject |
   14.36 EvidenceSynthesisEvidence |
   14.37 ExposureGroup |
   14.38 GroupAssignment |
   14.39 GroupR6 |
   14.40 Guideline |
   14.41 GuidelineRegistryRecord |
   14.42 InterventionOnlyEvidence |
   14.43 JournalArticleCitation |
   14.44 M11Report |
   14.45 MetaanalysisEligibilityCriteria |
   14.46 MetaanalysisOutcomeDefinition |
   14.47 MetaanalysisStudyGroup |
   14.48 NetEffectContribution |
   14.49 NetEffectContributionList |
   14.50 NetEffectContributions |
   14.51 NetEffectEstimate |
   14.52 NonComparativeEvidence |
   14.53 OutcomeDefinition |
   14.54 OutcomeImportance |
   14.55 OutcomeList |
   14.56 OutcomeMeasureReport |
   14.57 OutcomeVariablesList |
   14.58 ParticipantFlowEvidence |
   14.59 ParticipantFlowEvidenceVariable |
   14.60 ParticipantFlowReasonEvidenceVariable |
   14.61 ParticipantFlowReport |
   14.62 ParticipantFlowVariablesList |
   14.63 PreprintCitation |
   14.64 Rating |
   14.65 Recommendation |
   14.66 RecommendationAction |
   14.67 RecommendationEligibilityCriteria |
   14.68 RecommendationJustification |
   14.69 RecommendationPlan |
   14.70 RecommendationRating |
   14.71 ResearchStudyDataDictionary |
   14.72 ResearchStudySupport |
   14.73 RiskOfBias |
   14.74 SearchResults |
   14.75 SearchStrategy |
   14.76 SingleStudyEvidence |
   14.77 SoaPlanDefinition |
   14.78 SoftwareCitation |
   14.79 StatisticModel |
   14.80 StudyDesign |
   14.81 StudyEligibilityCriteria |
   14.82 StudyGroup |
   14.83 StudyRegistryRecord |
   14.84 SummaryOfFindings |
   14.85 SummaryOfNetEffect |
   14.86 SystematicReview |
   14.87 SystematicReviewEligibilityCriteria |
   14.88 SystematicReviewExcludedStudies |
   14.89 SystematicReviewIncludedStudies |
   14.90 VariableDefinition |
   14.91 WebPageCitation |
   14.92 AdditionalLanguage |
   14.93 ArtifactAssessmentCompared |
   14.94 ArtifactAssessmentDateAsRating |
   14.95 ArtifactPublicationStatus |
   14.96 CharacteristicTiming |
   14.97 CiteAs |
   14.98 CompositionExtendedContactDetail |
   14.99 EvidenceVariableHandlingDetail |
   14.100 GuidelineRegistration |
   14.101 NumberAnalyzed |
   14.102 PublicationDate |
   14.103 RelatesTo |
   14.104 RelatesToClassifier |
   14.105 RelatesToWithQuotation |
   14.106 RelativeOutcomeImportance |
   14.107 ResearchStudyExcludedStudy |
   14.108 ResearchStudyIncludedStudy |
   14.109 ResearchStudyIsLowInterventionTrial |
   14.110 ResearchStudyNumberOfStudiesIdentified |
   14.111 ResearchStudyNumberOfStudiesIncluded |
   14.112 ResearchStudySaeReportingMethod |
   14.113 ResearchStudySearchStrategy |
   14.114 ResearchStudySponsorConfidentialityStatement |
   14.115 ResearchStudyStudyAmendment |
   14.116 ResearchStudySystematicReviewEligibilityCriteria |
   14.117 StatisticModelExpression |
   14.118 StatisticModelIncludeIf |
   14.119 EBMonFHIR Profile Name Value Set |
   14.120 Evidence Rating System Classifier Codes Value Set |
   14.121 Recommendation Justification Classifier Codes Value Set |
   14.122 Research Study Document Types Value Set |
   14.123 Search Strategy Characteristic Value Set |
   14.124 EBMonFHIR Profile Name Code System |
   14.125 Evidence Rating System Classifier Code System |
   14.126 Research Study Document Types Code System |
   14.127 Search Strategy Characteristic Code System |
   14.128 11232013 Rosiglitazone monotherapy is effective in patients with type 2 diabetes. |
   14.129 14-day mortality remdesivir vs placebo meta-analysis (ACTT-1, Wang et al, WHO SOLIDARITY) |
   14.130 14706014 Chemohormonal therapy as primary treatment for metastatic prostate cancer: a randomized study of estramustine phosphate plus luteinizing hormone-releasing hormone agonist versus flutamide plus luteinizing hormone-releasing hormone agonist. |
   14.131 15832493 Spotlight on rosiglitazone in the management of type 2 diabetes mellitus. |
   14.132 15855602 Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. |
   14.133 179899 |
   14.134 18160893 Wonder woman. Like my childhood heroine, Mrs. Betty also had amazing powers. |
   14.135 18508207 A Phase 3 placebo-controlled, double-blind, multi-site trial of the alpha-2-adrenergic agonist, lofexidine, for opioid withdrawal. |
   14.136 19029421 Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer. |
   14.137 19091394 Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. |
   14.138 19967827 Wonder woman was Argentine and her real name was Evita. |
   14.139 22056152 Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. |
   14.140 22502942 Addition of radiotherapy to long-term androgen deprivation in locally advanced prostate cancer: an open randomised phase 3 trial. |
   14.141 23306100 Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. |
   14.142 23452809 Long-term follow-up of a phase II trial of chemotherapy plus hormone therapy for biochemical relapse after definitive local therapy for prostate cancer. |
   14.143 23589542 Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. |
   14.144 23604530 A phase II trial of androgen deprivation therapy (ADT) plus chemotherapy as initial treatment for local failures or advanced prostate cancer. |
   14.145 24598155 Long-term results of a phase II study with neoadjuvant docetaxel chemotherapy and complete androgen blockade in locally advanced and high-risk prostate cancer. |
   14.146 25301760 Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019). |
   14.147 26002607 Should docetaxel be standard of care for patients with metastatic hormone-sensitive prostate cancer? Pro and contra. |
   14.148 26028518 Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial. |
   14.149 26092557 Feasibility study of a randomized controlled trial comparing docetaxel chemotherapy and androgen deprivation therapy with sequential prostatic biopsies from patients with advanced non-castration-resistant prostate cancer. |
   14.150 26244877 Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. |
   14.151 26502880 A novel nasal powder formulation of glucagon: toxicology studies in animal models. |
   14.152 26681725 Intranasal Glucagon for Treatment of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes: A Randomized Crossover Noninferiority Study. |
   14.153 26859072 Emotional Distress in the Partners of Type 1 Diabetes Adults: Worries About Hypoglycemia and Other Key Concerns. |
   14.154 27222544 Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations. |
   14.155 27308831 Efficacy and Safety of Combined Androgen Deprivation Therapy (ADT) and Docetaxel Compared with ADT Alone for Metastatic Hormone-Naive Prostate Cancer: A Systematic Review and Meta-Analysis. |
   14.156 27979893 6. Glycemic Targets. |
   14.157 29114761 Web Exclusives. Annals Story Slam - How Wonder Woman Became My Alter Ego. |
   14.158 29114762 Web Exclusives. Annals Story Slam - Wonder Woman Is a Cartoon Character. |
   14.159 29202628 "I Kinda Feel Like Wonder Woman": An Interpretative Phenomenological Analysis of Pole Fitness and Positive Body Image. |
   14.160 29357271 Using Hawkeye from the Avengers to communicate on the eye. |
   14.161 29694275 A regressive formula of perversity: Wertham and the women of comics. |
   14.162 29694302 Introduction: "Suffering Sappho!": Lesbian content and queer female characters in comics. |
   14.163 30467172 Finding my inner Wonder Woman. |
   14.164 30545967 Parachute use to prevent death and major trauma when jumping from aircraft: randomized controlled trial. |
   14.165 34871555 What Can Wonder Woman Teach Radiologists? |
   14.166 35243488 Bariatric surgery and cardiovascular disease: a systematic review and meta-analysis. |
   14.167 36491989 Another Georgia Wonder Woman: She Does More Astounding Tricks Than Did Lula Hurst. |
   14.168 367832 |
   14.169 367833 |
   14.170 37024129 Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. |
   14.171 38584159 Efficacy and safety of a four-drug, quarter-dose treatment for hypertension: the QUARTET USA randomized trial. |
   14.172 6907780 Career guide: to change what needs changing...doesn't take Wonder Woman. |
   14.173 A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example |
   14.174 ADAS-Cog(11) EndpointAnalysisPlan from PHUSE Lilly Redacted Protocol - EBMonFHIR IG Version |
   14.175 Add-on Amlodipine at 6 weeks |
   14.176 Adults with diabetes mellitus type 2 |
   14.177 Adults with diabetes type 2 and established CVD (but no CKD) |
   14.178 Adults with type 2 diabetes, CVD and CKD |
   14.179 Adverse event free and hypertension control |
   14.180 Adverse event free and hypertension control at 12 weeks |
   14.181 Adverse Events Report for NCT03640312 |
   14.182 Age |
   14.183 Age with comparator |
   14.184 Age with intervention |
   14.185 Aircraft Type |
   14.186 Aircraft Type with comparator |
   14.187 Aircraft Type with intervention |
   14.188 Altitude |
   14.189 Altitude comparing intervention vs. comparator |
   14.190 Altitude for enrolled group |
   14.191 Altitude for screened group |
   14.192 Altitude with comparator |
   14.193 Altitude with intervention |
   14.194 Analyzed Group in PARACHUTE Trial |
   14.195 Anticoagulation for COVID-19 Combined RCTs in NEJM |
   14.196 Baseline Characteristics Report for NCT03640312 |
   14.197 Baseline Measure Report: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort) |
   14.198 Baseline Measures List for PARACHUTE Trial |
   14.199 BaselineMeasureEvidence: Age in 2018 Norwegian Cohort Medical Group |
   14.200 BaselineMeasureEvidence: Age in 2018 Norwegian Cohort Surgical Group |
   14.201 BaselineMeasureEvidence: BMI in 2018 Norwegian Cohort Medical Group |
   14.202 BaselineMeasureEvidence: BMI in 2018 Norwegian Cohort Surgical Group |
   14.203 BaselineVariablesList: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort) |
   14.204 Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials |
   14.205 BookCitation: Crossing the Quality Chasm: A New Health System for the 21st Century |
   14.206 BookPartCitation: Chapter 3 of Crossing the Quality Chasm: A New Health System for the 21st Century |
   14.207 BookPartCitation: Chapter 3 of Crossing the Quality Chasm: A New Health System for the 21st Century - without baseCitation |
   14.208 Candesartan 8 mg once daily |
   14.209 Certainty of Evidence Rating of 14-day mortality remdesivir vs placebo meta-analysis (ACTT-1, Wang et al, WHO SOLIDARITY) |
   14.210 Change in Mean Diastolic Blood Pressure (NCT03640312) |
   14.211 Change in Mean Diastolic Blood Pressure at 6 weeks for Candesartan in NCT03640312 |
   14.212 Change in Mean Diastolic Blood Pressure at 6 weeks for QUARTET LDQT in NCT03640312 |
   14.213 Change in Mean Diastolic Blood Pressure at 6 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312 |
   14.214 Change in Mean Systolic Blood Pressure (NCT03640312) |
   14.215 Change in Mean Systolic Blood Pressure (NCT03640312) |
   14.216 Change in Mean Systolic Blood Pressure at 12 weeks for Candesartan in NCT03640312 |
   14.217 Change in Mean Systolic Blood Pressure at 12 weeks for QUARTET LDQT in NCT03640312 |
   14.218 Change in Mean Systolic Blood Pressure at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312 |
   14.219 Change in Mean Systolic Blood Pressure at 6 weeks for Candesartan in NCT03640312 |
   14.220 Change in Mean Systolic Blood Pressure at 6 weeks for QUARTET LDQT in NCT03640312 |
   14.221 Change in Mean Systolic Blood Pressure at 6 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312 |
   14.222 CIBIC+ EndpointAnalysisPlan from PHUSE Lilly Redacted Protocol - EBMonFHIR IG Version |
   14.223 Citation for Composition: ComparativeEvidenceReport: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort) |
   14.224 Citation for EBMonFHIR Implementation Guide |
   14.225 Citation for FEvIR Evidence 55: 14-day mortality remdesivir vs placebo meta-analysis (ACTT-1, Wang et al, WHO SOLIDARITY) |
   14.226 Citation for FEvIR Evidence 7637: Critically appraised summary of primary outcome of multi-platform RCT of anticoagulation for non-critically ill COVID-19 |
   14.227 Classification: Study Design for Association of Bariatric Surgery with Complications and Comorbidities JAMA 2018 Norwegian Cohort |
   14.228 Comment on Guideline: ADA 2021 Standards of Medical Care 8. Obesity Management for the Treatment of Type 2 Diabetes by Joanne Dehnbostel 2023-11-28T15:19:01.266Z |
   14.229 Comparative Evidence Report for QUARTET USA Trial |
   14.230 ComparativeBaselineMeasureEvidence: Age in 2018 Norwegian Cohort Surgical Group vs. Medical Group |
   14.231 ComparativeBaselineMeasureEvidence: BMI in 2018 Norwegian Cohort Surgical Group vs. Medical Group |
   14.232 ComparativeEvidence: All-cause mortality effect of bariatric surgery in 2022 meta-analysis |
   14.233 ComparativeEvidence: Bariatric Surgery effect for ADA triple outcome at 5 years (Diabetes Surgery Study) |
   14.234 ComparativeEvidence: Bypass surgery effects on Additional GI surgical procedure in JAMA 2018 Norwegian cohort study |
   14.235 ComparativeEvidence: Bypass surgery effects on Myocardial infarction or stroke in Swedish Obese Subjects (SOS) study |
   14.236 ComparativeEvidence: Bypass surgery effects on New onset depression in JAMA 2018 Norwegian cohort study |
   14.237 ComparativeEvidence: Bypass surgery effects on Remission of diabetes in JAMA 2018 Norwegian cohort study |
   14.238 ComparativeEvidence: Bypass surgery effects on Treatment with opioids in JAMA 2018 Norwegian cohort study |
   14.239 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Courcoulas 2014 |
   14.240 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Courcoulas 2015 |
   14.241 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Cummings 2016 |
   14.242 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Ding 2015 |
   14.243 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Dixon 2008 |
   14.244 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Halperin 2014 |
   14.245 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Ikramuddin 2013 |
   14.246 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Ikramuddin 2015 |
   14.247 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Liang 2013 |
   14.248 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Mingrone 2012 (DIBASY) trial |
   14.249 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Mingrone 2015 (DIBASY) trial |
   14.250 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Parikh 2014 |
   14.251 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Schauer 2012 (STAMPEDE) trial |
   14.252 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Schauer 2014 (STAMPEDE) trial |
   14.253 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Wentworth 2014 |
   14.254 ComparativeEvidence: Mean difference in HbA1c effect of bariatric surgery in 2016 meta-analysis |
   14.255 ComparativeEvidenceReport: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort) |
   14.256 ComparativeEvidenceReportSubject: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort) |
   14.257 ComparativeEvidenceSynthesisReport: GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk |
   14.258 ComparativeParticipantFlowEvidence: Dropout due to stopping intervention Lofexidine vs. Placebo in opioid detoxification trial |
   14.259 ComparatorDefinition: Glucagon-Like Peptide-1 (GLP-1) receptor agonists |
   14.260 ComparatorDefinition: Obese patients ≥ 18 years old without bariatric surgery |
   14.261 ComparatorDefinition: Standard care |
   14.262 ComparatorGroup: JAMA 2018 Norwegian cohort study Control cohort |
   14.263 ComparatorOnlyEvidence: Additional GI surgical procedure without bariatric surgery (Control Group) in JAMA 2018 Norwegian cohort study |
   14.264 ComparatorOnlyEvidence: All-cause mortality without bariatric surgery in 2022 meta-analysis |
   14.265 ComparatorOnlyEvidence: Myocardial infarction or stroke without bariatric surgery (Control Group) in Swedish Obese Subjects (SOS) study |
   14.266 ComparatorOnlyEvidence: New onset depression without bariatric surgery (Control Group) in JAMA 2018 Norwegian cohort study |
   14.267 ComparatorOnlyEvidence: Remission of diabetes without bariatric surgery (Control Group) in JAMA 2018 Norwegian cohort study |
   14.268 ComparatorOnlyEvidence: Treatment with opioids without bariatric surgery (Control Group) in JAMA 2018 Norwegian cohort study |
   14.269 Comparison: Original and Adapted Recommendation: ADA Obesity Management Recommendation 8.16 |
   14.270 Composite Rating of FOI 153881 for Project FOI 112280 |
   14.271 Computable_Publishing_LLC |
   14.272 ConceptualCohortDefinition: At least 2 risk factors for stroke |
   14.273 ConceptualCohortDefinition: BMI 27.5-32.4 in Asian Americans who do not achieve durable weight loss and improvement in comorbidities without surgery |
   14.274 ConceptualCohortDefinition: BMI 30-34.9 in persons who do not achieve durable weight loss and improvement in comorbidities without surgery |
   14.275 ConceptualCohortDefinition: BMI 32.5-37.4 in Asian Americans who do not achieve durable weight loss and improvement in comorbidities without surgery |
   14.276 ConceptualCohortDefinition: BMI 35-39.9 in persons who do not achieve durable weight loss and improvement in comorbidities without surgery |
   14.277 ConceptualCohortDefinition: BMI criteria for ADA surgery recommendation |
   14.278 ConceptualCohortDefinition: BMI ≥ 35 and at least 1 obesity-related comorbidity |
   14.279 ConceptualCohortDefinition: BMI ≥ 37.5 kg/m2 in Asian Americans |
   14.280 ConceptualCohortDefinition: Estimated glomerular filtration rate 45-59 |
   14.281 ConceptualCohortDefinition: Heart failure based on Phenotypes |
   14.282 ConceptualCohortDefinition: Lower BMI criteria for ADA surgery consideration |
   14.283 ConceptualCohortDefinition: Meet either T1DM-specific eligibility criteria or T2DM-specific eligibility criteria |
   14.284 ConceptualCohortDefinition: Nonfatal myocardial infarction |
   14.285 ConceptualCohortDefinition: Nonfatal stroke |
   14.286 ConceptualCohortDefinition: Oxygen saturation < 96% on Boots Finger Pulse Oximeter |
   14.287 ConceptualCohortDefinition: Oxygen saturation < 96% on Boots Finger Pulse Oximeter with Ranges |
   14.288 ConceptualCohortDefinition: Proxy criteria for surgical candidates |
   14.289 ConceptualCohortDefinition: Severe obesity |
   14.290 ConceptualCohortDefinition: T1DM or T2DM |
   14.291 ConceptualCohortDefinition: T1DM-specific criteria |
   14.292 ConceptualCohortDefinition: T2DM-specific criteria |
   14.293 ConceptualCohortDefinition_Cancer_of_any_kind_except_basal_cell_skin_cancer_or_cancer_in_situ_unless_documented_to_be_disease_free_for_five_years |
   14.294 ConceptualCohortDefinition_Cardiovascular_event |
   14.295 ConceptualComparatorDefinition: NOT Bariatric Surgery (RYGB, VSG, LAGB, BPD) |
   14.296 ConceptualComparatorDefinition: Usual-care pharmacologic thromboprophylaxis |
   14.297 ConceptualExposureDefinition: Bariatric Surgery (RYGB, VSG, LAGB, BPD) |
   14.298 ConceptualExposureDefinition: Therapeutic-dose anticoagulation with heparin |
   14.299 COVID_19PneumoniaHospitalizedAdult |
   14.300 Critically appraised summary of primary outcome of multi-platform RCT of anticoagulation for non-critically ill patients with COVID-19 |
   14.301 CTIS2024-516402-32-00 Eligibility Criteria |
   14.302 CTIS2024-516402-32-00 Primary Outcome 1 |
   14.303 CTIS2024-516402-32-00 Secondary Outcome 1 |
   14.304 CTIS2024-516402-32-00 Secondary Outcome 2 |
   14.305 CTIS2024-516402-32-00 Secondary Outcome 3 |
   14.306 CTIS2024-516402-32-00 Secondary Outcome 4 |
   14.307 CTIS2024-516402-32-00 Secondary Outcome 5 |
   14.308 CTIS2024-516402-32-00 Secondary Outcome 6 |
   14.309 CTIS2024-516402-32-00 Secondary Outcome 7 |
   14.310 CTIS2024-516402-32-00 Secondary Outcome 8 |
   14.311 DatabaseCitation: Citation for FEvIR Platform |
   14.312 DatabaseEntryCitation: ComparativeEvidenceReport: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort) |
   14.313 DatasetCitation: Extrachromosomal DNA Amplification Contributes to Small Cell Lung Cancer Heterogeneity and is Associated with Worse Outcomes |
   14.314 DateOfFirstPublication Classification of FOI 153881 by Rachel Couban |
   14.315 Death or Major Traumatic Injury 30 days after Impact comparing intervention vs. comparator |
   14.316 Death or Major Traumatic Injury 30 days after Impact with comparator |
   14.317 Death or Major Traumatic Injury 30 days after Impact with intervention |
   14.318 Death or Major Traumatic Injury on Impact comparing intervention vs. comparator |
   14.319 declined randomization in PARACHUTE Study |
   14.320 deemed unsuitable by investigator in PARACHUTE Trial |
   14.321 Delany-Moretlwe 2022 clinical trial |
   14.322 Diabetes treatment medication |
   14.323 Diastolic blood pressure at 12 weeks |
   14.324 DichotomousIntendedOutcome: Death or Major Traumatic Injury within 30 days |
   14.325 Eculizumab in hypertensive emergency-associated hemolytic uremic syndrome: a randomized multicenter controlled trial (HYPERSHU) |
   14.326 Efficacy and Safety of a Quadruple Ultra-low-dose Treatment for Hypertension |
   14.327 Eligibility criteria for NMA_Diabetes |
   14.328 Eligibility Criteria for QUARTET USA Trial |
   14.329 Enrolled Group for QUARTET USA Trial |
   14.330 Enrolled Group PARACHUTE Trial |
   14.331 Ethnic Group |
   14.332 Ethnic Group with comparator |
   14.333 Ethnic Group with intervention |
   14.334 Evidence Based Medicine on FHIR Implementation Guide Code System |
   14.335 Evidence for Results for Add-on Amlodipine at 6 weeks in GroupAssignment: Quadpill vs. Candesartan |
   14.336 Evidence for Results for Add-on Amlodipine at 6 weeks in QUARTET USA Trial Control Group |
   14.337 Evidence for Results for Add-on Amlodipine at 6 weeks in QUARTET USA Trial Quadpill group |
   14.338 Evidence for Results for Adverse event free and hypertension control at 12 weeks in GroupAssignment: Quadpill vs. Candesartan |
   14.339 Evidence for Results for Adverse event free and hypertension control at 12 weeks in QUARTET USA Trial Control Group |
   14.340 Evidence for Results for Adverse event free and hypertension control at 12 weeks in QUARTET USA Trial Quadpill group |
   14.341 Evidence for Results for Diastolic blood pressure at 12 weeks in GroupAssignment: Quadpill vs. Candesartan |
   14.342 Evidence for Results for Diastolic blood pressure at 12 weeks in QUARTET USA Trial Control Group |
   14.343 Evidence for Results for Diastolic blood pressure at 12 weeks in QUARTET USA Trial Quadpill group |
   14.344 Evidence for Results for Hypertension Control at 12 weeks in GroupAssignment: Quadpill vs. Candesartan |
   14.345 Evidence for Results for Hypertension Control at 12 weeks in QUARTET USA Trial Control Group |
   14.346 Evidence for Results for Hypertension Control at 12 weeks in QUARTET USA Trial Quadpill group |
   14.347 Evidence for Results for Medication Adherence at 12 weeks in GroupAssignment: Quadpill vs. Candesartan |
   14.348 Evidence for Results for Medication Adherence at 12 weeks in QUARTET USA Trial Control Group |
   14.349 Evidence for Results for Medication Adherence at 12 weeks in QUARTET USA Trial Quadpill group |
   14.350 Evidence for Results for Systolic blood pressure at 12 weeks in GroupAssignment: Quadpill vs. Candesartan |
   14.351 Evidence for Results for Systolic blood pressure at 12 weeks in QUARTET USA Trial Control Group |
   14.352 Evidence for Results for Systolic blood pressure at 12 weeks in QUARTET USA Trial Quadpill group |
   14.353 Evidence List: Effect estimates for meta-analysis (Biegel 2020, Wang 2020, SOLIDARITY) |
   14.354 EvidenceList: Study results included in Mean difference in HbA1c effect of bariatric surgery in 2016 meta-analysis |
   14.355 EvidenceReportSectionCode Value Set |
   14.356 EvidenceReportSubject: Clinical Outcomes for Effects of Bariatric Surgery |
   14.357 EvidenceVariable Handling Extension Value Set |
   14.358 EvidenceVariable: case_id |
   14.359 EvidenceVariable: Patient id |
   14.360 EvidenceVariable: Time of measurement |
   14.361 Example EndpointAnalysisPlan from PHUSE Lilly Redacted Protocol - EBMonFHIR IG Version |
   14.362 Excluded from PARACHUTE Study |
   14.363 ExposureGroup: JAMA 2018 Norwegian cohort study Surgery cohort |
   14.364 ExposureVariable: Age (as continuous variable) |
   14.365 ExposureVariable: Body Mass Index (as continuous variable) |
   14.366 ExposureVariable: pht013093.v1.p1 Age at diagnosis |
   14.367 ExposureVariable: pht013093.v1.p1 RACE |
   14.368 ExposureVariable: pht013093.v1.p1 SEX |
   14.369 ExposureVariable: pht013093.v1.p1 SUBJECT_ID |
   14.370 ExposureVariable: pht013094.v1.p1 ANALYTE_TYPE |
   14.371 ExposureVariable: pht013094.v1.p1 BODY_SITE |
   14.372 ExposureVariable: pht013094.v1.p1 IS_TUMOR |
   14.373 ExposureVariable: pht013094.v1.p1 SAMPLE_ID |
   14.374 ExposureVariable: pht013094.v1.p1 SAMPLE_USE |
   14.375 ExposureVariable: pht013094.v1.p1 Source_Type |
   14.376 Family History of Parachute Use |
   14.377 Family History of Parachute Use with comparator |
   14.378 Family History of Parachute Use with intervention |
   14.379 Frequent Flier |
   14.380 Frequent Flier with comparator |
   14.381 Frequent Flier with intervention |
   14.382 GLP-1 RA Group in Adults with diabetes type 2 with moderate CV risk |
   14.383 GLP-1 RA Group in Adults with type 2 diabetes |
   14.384 Glucagon Hydrochloride Solution (Active Comparator) |
   14.385 Glucagon Nasal Powder (Experimental) |
   14.386 Group Randomized to Comparator (empty backpack) in PARACHUTE Trial |
   14.387 Group Randomized to Intervention Group (parachute) in PARACHUTE Trial |
   14.388 GroupAssignment: Bariatric Surgery vs. no bariatric surgery |
   14.389 GroupAssignment: ExposureDefinition: Bariatric Surgery (RYGB, VSG, LAGB, BPD) vs. ComparatorDefinition: NOT Bariatric Surgery (RYGB, VSG, LAGB, BPD) |
   14.390 GroupAssignment: ExposureGroup: JAMA 2018 Norwegian cohort study Surgery cohort vs. ComparatorGroup: JAMA 2018 Norwegian cohort study Control cohort |
   14.391 GroupAssignment: GLP-1 RA vs. Standard care |
   14.392 GroupAssignment: high dose xanomeline vs. low dose xanomeline vs. placebo |
   14.393 GroupAssignment: Jumping from aircraft with parachute vs. Jumping from aircraft with empty backpack |
   14.394 GroupAssignment: Non Participants vs. Enrolled Participants |
   14.395 GroupAssignment: Quadpill vs. Candesartan |
   14.396 GroupAssignment: Roux-en-Y gastric bypass or Biliopancreatic Diversion vs. medical treatment |
   14.397 GroupAssignment: Roux-en-Y gastric bypass surgery vs. Lifestyle-intensive medical management intervention alone |
   14.398 GroupAssignment: Roux-en-Y gastric bypass vs. medical treatment |
   14.399 GroupAssignment: SGLT2 inhibitors vs. GLP-1 RA |
   14.400 GroupAssignment: Therapeutic-dose anticoagulation with heparin vs. Usual-care pharmacologic thromboprophylaxis |
   14.401 Guideline: ADA 2021 Standards of Medical Care 8. Obesity Management for the Treatment of Type 2 Diabetes |
   14.402 Health Survey Score Total |
   14.403 Health Survey Score Total comparing intervention vs. comparator |
   14.404 Health Survey Score Total with comparator |
   14.405 Health Survey Score Total with intervention |
   14.406 Health Survey Score-Mental Health Subscore |
   14.407 Health Survey Score-Mental Health Subscore comparing intervention vs. comparator |
   14.408 Health Survey Score-Mental Health Subscore with comparator |
   14.409 Health Survey Score-Mental Health Subscore with intervention |
   14.410 Health Survey Score-Physical Health Subscore |
   14.411 Health Survey Score-Physical Health Subscore comparing intervention vs. comparator |
   14.412 Health Survey Score-Physical Health Subscore with comparator |
   14.413 Health Survey Score-Physical Health Subscore with intervention |
   14.414 Health-related Quality of Life (NCT03640312) |
   14.415 Health-related Quality of Life at 12 weeks - Change in Mental Health T score (PROMIS) at (NCT03640312) |
   14.416 Health-related Quality of Life at 12 weeks - Change in Mental Health T score (PROMIS) for Candesartan in NCT03640312 |
   14.417 Health-related Quality of Life at 12 weeks - Change in Mental Health T score (PROMIS) for QUARTET LDQT in NCT03640312 |
   14.418 Health-related Quality of Life at 12 weeks - Change in Physical Health T score (PROMIS) at (NCT03640312) |
   14.419 Health-related Quality of Life at 12 weeks - Change in Physical Health T score (PROMIS) for Candesartan in NCT03640312 |
   14.420 Health-related Quality of Life at 12 weeks - Change in Physical Health T score (PROMIS) for QUARTET LDQT in NCT03640312 |
   14.421 Health-related Quality of Life at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312 |
   14.422 Health-related Quality of Life at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312 |
   14.423 Height |
   14.424 Height with comparator |
   14.425 Height with intervention |
   14.426 High Blood Pressure Medication Value Set |
   14.427 History of Acrophobia |
   14.428 History of Acrophobia with comparator |
   14.429 History of Acrophobia with intervention |
   14.430 History of Broken Bones |
   14.431 History of Broken Bones with comparator |
   14.432 History of Broken Bones with intervention |
   14.433 History of Parachute Use |
   14.434 History of Parachute Use with comparator |
   14.435 History of Parachute Use with intervention |
   14.436 Hypertension Control at 12 weeks |
   14.437 ICD-10-GM Terminale Codes |
   14.438 Injury Severity Score 30 days after Impact comparing intervention vs. comparator |
   14.439 Injury Severity Score 30 days after Impact with comparator |
   14.440 Injury Severity Score 30 days after Impact with intervention |
   14.441 Injury Severity Score on Impact comparing intervention vs. comparator |
   14.442 Injury Severity Score on Impact with comparator |
   14.443 Injury Severity Score on Impact with intervention |
   14.444 International vs Domestic Flight |
   14.445 International vs Domestic Flight with comparator |
   14.446 International vs Domestic Flight with intervention |
   14.447 InterventionDefinition: Glucagon-Like Peptide-1 (GLP-1) receptor agonists |
   14.448 InterventionDefinition: Sodium-Glucose Transport Protein 2 (SGLT2) inhibitors |
   14.449 InterventionOnlyEvidence: Additional GI surgical procedure with bariatric surgery (Intervention Group) in JAMA 2018 Norwegian cohort study |
   14.450 InterventionOnlyEvidence: New onset depression with bariatric surgery (Intervention Group) in JAMA 2018 Norwegian cohort study |
   14.451 InterventionOnlyEvidence: Remission of diabetes with bariatric surgery (Intervention Group) in JAMA 2018 Norwegian cohort study |
   14.452 InterventionOnlyEvidence: Treatment with opioids with bariatric surgery (Intervention Group) in JAMA 2018 Norwegian cohort study |
   14.453 Investigator |
   14.454 Investigator-by-treatment interaction for ADAS-Cog(11) ANCOVA |
   14.455 IV remdesivir 200 mg then 100 mg/day for 9 days |
   14.456 Joanne Dehnbostel's Adaptation Report of Recommendation: ADA Obesity Management Recommendation 8.16 |
   14.457 JournalArticleCitation: ADA 2021 Standards of Medical Care 8. Obesity Management for the Treatment of Type 2 Diabetes |
   14.458 JournalArticleCitation: Association of Bariatric Surgery with Complications and Comorbidities JAMA 2018 Norwegian Cohort |
   14.459 Jumping from aircraft with empty backpack |
   14.460 Jumping from aircraft with parachute |
   14.461 Justification for Recommendation: ADA Obesity Management Recommendation 8.16 |
   14.462 Justification for Recommendation: ADA Obesity Management Recommendation 8.17 |
   14.463 M11 IGBJ Protocol Example Eligibility Criteria |
   14.464 M11 IGBJ Protocol Example for EBMonFHIR IG |
   14.465 M11 Report Template Instructions |
   14.466 MAGIC-derived ComparatorOnlyEvidence: All-cause mortality in GLP-1 RA Group in Adults with type 2 diabetes |
   14.467 MAGIC-derived ComparatorOnlyEvidence: All-cause mortality in Standard care Group in Adults with type 2 diabetes with moderate CV risk |
   14.468 MAGIC-derived ComparatorOnlyEvidence: Body weight in GLP-1 RA Group in Adults with type 2 diabetes |
   14.469 MAGIC-derived ComparatorOnlyEvidence: Body weight in Standard care Group in Adults with type 2 diabetes with moderate CV risk |
   14.470 MAGIC-derived ComparatorOnlyEvidence: Cardiovascular mortality in GLP-1 RA Group in Adults with type 2 diabetes |
   14.471 MAGIC-derived ComparatorOnlyEvidence: Cardiovascular mortality in Standard care Group in Adults with type 2 diabetes with moderate CV risk |
   14.472 MAGIC-derived ComparatorOnlyEvidence: Diabetic ketoacidosis in GLP-1 RA Group in Adults with type 2 diabetes |
   14.473 MAGIC-derived ComparatorOnlyEvidence: End-stage kidney disease in GLP-1 RA Group in Adults with type 2 diabetes |
   14.474 MAGIC-derived ComparatorOnlyEvidence: End-stage kidney disease in Standard care Group in Adults with type 2 diabetes with moderate CV risk |
   14.475 MAGIC-derived ComparatorOnlyEvidence: Genital infection in GLP-1 RA Group in Adults with type 2 diabetes |
   14.476 MAGIC-derived ComparatorOnlyEvidence: Health-related quality of life in GLP-1 RA Group in Adults with type 2 diabetes |
   14.477 MAGIC-derived ComparatorOnlyEvidence: Health-related quality of life in Standard care Group in Adults with type 2 diabetes with moderate CV risk |
   14.478 MAGIC-derived ComparatorOnlyEvidence: Heart failure in GLP-1 RA Group in Adults with type 2 diabetes |
   14.479 MAGIC-derived ComparatorOnlyEvidence: Heart failure in Standard care Group in Adults with type 2 diabetes with moderate CV risk |
   14.480 MAGIC-derived ComparatorOnlyEvidence: Nonfatal myocardial infarction in GLP-1 RA Group in Adults with type 2 diabetes |
   14.481 MAGIC-derived ComparatorOnlyEvidence: Nonfatal myocardial infarction in Standard care Group in Adults with type 2 diabetes with moderate CV risk |
   14.482 MAGIC-derived ComparatorOnlyEvidence: Nonfatal stroke in GLP-1 RA Group in Adults with type 2 diabetes |
   14.483 MAGIC-derived ComparatorOnlyEvidence: Nonfatal stroke in Standard care Group in Adults with type 2 diabetes with moderate CV risk |
   14.484 MAGIC-derived ComparatorOnlyEvidence: Serious hyperglycaemia in GLP-1 RA Group in Adults with type 2 diabetes |
   14.485 MAGIC-derived ComparatorOnlyEvidence: Serious hyperglycaemia in Standard care Group in Adults with type 2 diabetes with moderate CV risk |
   14.486 MAGIC-derived ComparatorOnlyEvidence: Severe gastrointestinal events in GLP-1 RA Group in Adults with type 2 diabetes |
   14.487 MAGIC-derived ComparatorOnlyEvidence: Severe gastrointestinal events in Standard care Group in Adults with type 2 diabetes with moderate CV risk |
   14.488 MAGIC-derived Evidence: All-cause mortality with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk |
   14.489 MAGIC-derived Evidence: All-cause mortality with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes |
   14.490 MAGIC-derived Evidence: Body weight with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk |
   14.491 MAGIC-derived Evidence: Body weight with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes |
   14.492 MAGIC-derived Evidence: Cardiovascular mortality with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk |
   14.493 MAGIC-derived Evidence: Cardiovascular mortality with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes |
   14.494 MAGIC-derived Evidence: Diabetic ketoacidosis with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes |
   14.495 MAGIC-derived Evidence: End-stage kidney disease with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk |
   14.496 MAGIC-derived Evidence: End-stage kidney disease with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes |
   14.497 MAGIC-derived Evidence: Genital infection with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes |
   14.498 MAGIC-derived Evidence: Health-related quality of life with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk |
   14.499 MAGIC-derived Evidence: Health-related quality of life with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes |
   14.500 MAGIC-derived Evidence: Heart failure with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk |
   14.501 MAGIC-derived Evidence: Heart failure with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes |
   14.502 MAGIC-derived Evidence: Nonfatal myocardial infarction with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk |
   14.503 MAGIC-derived Evidence: Nonfatal myocardial infarction with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes |
   14.504 MAGIC-derived Evidence: Nonfatal stroke with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk |
   14.505 MAGIC-derived Evidence: Nonfatal stroke with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes |
   14.506 MAGIC-derived Evidence: Serious hyperglycaemia with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk |
   14.507 MAGIC-derived Evidence: Serious hyperglycaemia with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes |
   14.508 MAGIC-derived Evidence: Severe gastrointestinal events with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk |
   14.509 MAGIC-derived Evidence: Severe gastrointestinal events with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes |
   14.510 MAGIC-derived InterventionOnlyEvidence: All-cause mortality in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk |
   14.511 MAGIC-derived InterventionOnlyEvidence: All-cause mortality in SGLT2 inhibitors Group in Adults with type 2 diabetes |
   14.512 MAGIC-derived InterventionOnlyEvidence: Body weight in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk |
   14.513 MAGIC-derived InterventionOnlyEvidence: Body weight in SGLT2 inhibitors Group in Adults with type 2 diabetes |
   14.514 MAGIC-derived InterventionOnlyEvidence: Cardiovascular mortality in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk |
   14.515 MAGIC-derived InterventionOnlyEvidence: Cardiovascular mortality in SGLT2 inhibitors Group in Adults with type 2 diabetes |
   14.516 MAGIC-derived InterventionOnlyEvidence: Diabetic ketoacidosis in SGLT2 inhibitors Group in Adults with type 2 diabetes |
   14.517 MAGIC-derived InterventionOnlyEvidence: End-stage kidney disease in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk |
   14.518 MAGIC-derived InterventionOnlyEvidence: End-stage kidney disease in SGLT2 inhibitors Group in Adults with type 2 diabetes |
   14.519 MAGIC-derived InterventionOnlyEvidence: Genital infection in SGLT2 inhibitors Group in Adults with type 2 diabetes |
   14.520 MAGIC-derived InterventionOnlyEvidence: Health-related quality of life in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk |
   14.521 MAGIC-derived InterventionOnlyEvidence: Health-related quality of life in SGLT2 inhibitors Group in Adults with type 2 diabetes |
   14.522 MAGIC-derived InterventionOnlyEvidence: Heart failure in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk |
   14.523 MAGIC-derived InterventionOnlyEvidence: Heart failure in SGLT2 inhibitors Group in Adults with type 2 diabetes |
   14.524 MAGIC-derived InterventionOnlyEvidence: Nonfatal myocardial infarction in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk |
   14.525 MAGIC-derived InterventionOnlyEvidence: Nonfatal myocardial infarction in SGLT2 inhibitors Group in Adults with type 2 diabetes |
   14.526 MAGIC-derived InterventionOnlyEvidence: Nonfatal stroke in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk |
   14.527 MAGIC-derived InterventionOnlyEvidence: Nonfatal stroke in SGLT2 inhibitors Group in Adults with type 2 diabetes |
   14.528 MAGIC-derived InterventionOnlyEvidence: Serious hyperglycaemia in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk |
   14.529 MAGIC-derived InterventionOnlyEvidence: Serious hyperglycaemia in SGLT2 inhibitors Group in Adults with type 2 diabetes |
   14.530 MAGIC-derived InterventionOnlyEvidence: Severe gastrointestinal events in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk |
   14.531 MAGIC-derived InterventionOnlyEvidence: Severe gastrointestinal events in SGLT2 inhibitors Group in Adults with type 2 diabetes |
   14.532 Mean Change in Blood Urea Nitrogen (NCT03640312) |
   14.533 Mean Change in Blood Urea Nitrogen at 12 weeks for Candesartan in NCT03640312 |
   14.534 Mean Change in Blood Urea Nitrogen at 12 weeks for QUARTET LDQT in NCT03640312 |
   14.535 Mean Change in Blood Urea Nitrogen at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312 |
   14.536 Mean Change in Serum Creatinine (NCT03640312) |
   14.537 Mean Change in Serum Creatinine at 12 weeks for Candesartan in NCT03640312 |
   14.538 Mean Change in Serum Creatinine at 12 weeks for QUARTET LDQT in NCT03640312 |
   14.539 Mean Change in Serum Creatinine at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312 |
   14.540 Mean Change in Serum Potassium (NCT03640312) |
   14.541 Mean Change in Serum Potassium at 12 weeks for Candesartan in NCT03640312 |
   14.542 Mean Change in Serum Potassium at 12 weeks for QUARTET LDQT in NCT03640312 |
   14.543 Mean Change in Serum Potassium at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312 |
   14.544 Mean Change in Serum Sodium (NCT03640312) |
   14.545 Mean Change in Serum Sodium at 12 weeks for Candesartan in NCT03640312 |
   14.546 Mean Change in Serum Sodium at 12 weeks for QUARTET LDQT in NCT03640312 |
   14.547 Mean Change in Serum Sodium at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312 |
   14.548 Mean Diastolic Blood Pressure (NCT03640312) |
   14.549 Mean Diastolic Blood Pressure at 6 weeks for Candesartan in NCT03640312 |
   14.550 Mean Diastolic Blood Pressure at 6 weeks for QUARTET LDQT in NCT03640312 |
   14.551 Mean Diastolic Blood Pressure at 6 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312 |
   14.552 Mean Systolic Blood Pressure (NCT03640312) |
   14.553 Mean Systolic Blood Pressure at 6 weeks for Candesartan in NCT03640312 |
   14.554 Mean Systolic Blood Pressure at 6 weeks for QUARTET LDQT in NCT03640312 |
   14.555 Mean Systolic Blood Pressure at 6 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312 |
   14.556 Median Age of Parachute Intervention Group |
   14.557 Medication Adherence (NCT03640312) |
   14.558 Medication Adherence at 12 weeks |
   14.559 Medication Adherence at 12 weeks for Candesartan in NCT03640312 |
   14.560 Medication Adherence at 12 weeks for QUARTET LDQT in NCT03640312 |
   14.561 Medication Adherence at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312 |
   14.562 MetaanalysisEligibilityCriteria: Mean difference in HbA1c effect of bariatric surgery in type 2 diabetes and elevated BMI in 2016 meta-analysis |
   14.563 MetaanalysisOutcomeDefinition: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups at end of follow-up |
   14.564 MetaanalysisStudyGroup: Effect Estimates for Mortality at 14 days from COVID19 Remdesivir vs. Placebo RCTs |
   14.565 MetaanalysisStudyGroup: Study results included in Mean difference in HbA1c effect of bariatric surgery in 2016 meta-analysis |
   14.566 Mortality at 14 days |
   14.567 NCT03640312 Eligibility Criteria |
   14.568 NetEffectContribution: Additional GI surgical procedure for Example for GIN 2022 |
   14.569 NetEffectContribution: All-cause mortality for Example for GIN 2022 |
   14.570 NetEffectContribution: New onset depression for Example for GIN 2022 |
   14.571 NetEffectContribution: Nonfatal myocardial infarction or stroke for Example for GIN 2022 |
   14.572 NetEffectContribution: Remission of diabetes for Example for GIN 2022 |
   14.573 NetEffectContribution: Treatment with opioids for Example for GIN 2022 |
   14.574 NetEffectContributionList: Bariatric Surgery Example for GIN 2022 |
   14.575 NetEffectContributions: Bariatric Surgery Example for GIN 2022 |
   14.576 NetEffectEstimate: Bariatric Surgery Example for GIN 2022 |
   14.577 NHANES LBDGLUSI Variable Definition Cohort Definition |
   14.578 NHANES LBDGLUSI: Fasting Glucose (mmol/L) |
   14.579 NHANES LBXGLU Variable Definition Cohort Definition |
   14.580 NHANES LBXGLU: Fasting Glucose (mg/dL) |
   14.581 NHANES Plasma Fasting Glucose (GLU_J) Data Dictionary |
   14.582 NHANES SEQN Respondent Sequence Number |
   14.583 NHANES WTSAF2YR Variable Definition Cohort Definition |
   14.584 NHANES WTSAF2YR: Fasting Subsample 2 Year MEC Weight |
   14.585 Norwegian Cohort Study Comparing Bariatric Surgery vs Medical Obesity Treatment for Long-term Medical Complications and Obesity-Related Comorbidities |
   14.586 NT-proBNP Study Data Dictionary |
   14.587 Number of Patients Requiring Step up Treatment (NCT03640312) |
   14.588 Number of Patients Requiring Step up Treatment at 6 weeks for Candesartan in NCT03640312 |
   14.589 Number of Patients Requiring Step up Treatment at 6 weeks for QUARTET LDQT in NCT03640312 |
   14.590 Number of Patients Requiring Step up Treatment at 6 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312 |
   14.591 Organ support-free days |
   14.592 Outcome Definition: All-cause mortality |
   14.593 Outcome Definition: Body weight |
   14.594 Outcome Definition: Cardiovascular mortality |
   14.595 Outcome Definition: End-stage kidney disease |
   14.596 Outcome Definition: Health-related quality of life |
   14.597 Outcome Definition: Heart failure |
   14.598 Outcome Definition: Nonfatal myocardial infarction |
   14.599 Outcome Definition: Nonfatal stroke |
   14.600 Outcome Definition: Serious hyperglycaemia |
   14.601 Outcome Definition: Severe gastrointestinal events |
   14.602 Outcome Importance Rating 100 of All-cause mortality |
   14.603 Outcome Importance Rating 30 of Nonfatal myocardial infarction or stroke |
   14.604 Outcome Importance Rating 5 of New onset depression |
   14.605 Outcome Importance Rating 5 of Remission of diabetes |
   14.606 Outcome Importance Rating 5 of Treatment with opioids |
   14.607 Outcome Importance Rating 8 of Additional GI surgical procedure |
   14.608 Outcome Measure List for QUARTET USA Trial |
   14.609 Outcome Measure Report for QUARTET USA Trial |
   14.610 Outcome Measure Report: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort) |
   14.611 Outcome Measures Report for NCT03640312 |
   14.612 Outcome Variables List for PARACHUTE Trial |
   14.613 Outcome: Death or Major Traumatic Injury 30 days after Impact |
   14.614 Outcome: Death or Major Traumatic Injury on Impact |
   14.615 Outcome: Injury Severity Score 30 days after Impact |
   14.616 Outcome: Injury Severity Score on Impact |
   14.617 OutcomeDefinition: Injury Severity Score on Impact |
   14.618 OutcomeDefinition: All-cause mortality |
   14.619 OutcomeDefinition: American Diabetes Association composite triple end point for metabolic control |
   14.620 OutcomeDefinition: Body weight |
   14.621 OutcomeDefinition: Cardiovascular mortality |
   14.622 OutcomeDefinition: Diabetes in remission |
   14.623 OutcomeDefinition: Diabetic ketoacidosis |
   14.624 OutcomeDefinition: End-stage kidney disease |
   14.625 OutcomeDefinition: Genital infection |
   14.626 OutcomeDefinition: HbA1c at 12 months |
   14.627 OutcomeDefinition: HbA1c at 24 months |
   14.628 OutcomeDefinition: HbA1c at 36 months |
   14.629 OutcomeDefinition: HbA1c at 6 months |
   14.630 OutcomeDefinition: HbA1c at 60 months |
   14.631 OutcomeDefinition: Health-related quality of life |
   14.632 OutcomeDefinition: Heart failure |
   14.633 OutcomeDefinition: Mortality at 14 days |
   14.634 OutcomeDefinition: New onset depression |
   14.635 OutcomeDefinition: Nonfatal myocardial infarction |
   14.636 OutcomeDefinition: Nonfatal myocardial infarction or stroke |
   14.637 OutcomeDefinition: Nonfatal stroke |
   14.638 OutcomeDefinition: Serious hyperglycaemia |
   14.639 OutcomeDefinition: Severe gastrointestinal events |
   14.640 OutcomeList: Clinical Outcomes for Effects of Bariatric Surgery |
   14.641 OutcomeMeasureReport: GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk |
   14.642 OutcomeVariable: American Diabetes Association composite triple end point for metabolic control at 5 years |
   14.643 OutcomeVariable: HbA1c at 12 months |
   14.644 OutcomeVariable: HbA1c at 24 months |
   14.645 OutcomeVariable: HbA1c at 36 months |
   14.646 OutcomeVariable: HbA1c at 6 months |
   14.647 OutcomeVariable: HbA1c at 60 months |
   14.648 OutcomeVariable: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups at end of follow-up |
   14.649 OutcomeVariable: New onset depression |
   14.650 OutcomeVariable: Nonfatal myocardial infarction or stroke |
   14.651 OutcomeVariable: Remission of diabetes |
   14.652 OutcomeVariablesList: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort) |
   14.653 OutcomeVariable_Additional_GI_surgical_procedure |
   14.654 OutcomeVariable_All_cause_mortality |
   14.655 OutcomeVariable_Treatment_with_opioids |
   14.656 PARACHUTE Trial baseline characteristics |
   14.657 PARACHUTE Trial non participants |
   14.658 PARACHUTE trial participant flow report |
   14.659 PARACHUTE Trial Participants |
   14.660 PARACHUTE Trial Participants assigned an empty backpack |
   14.661 PARACHUTE trial participants assigned parachute |
   14.662 PARACHUTE Trial Participants available for randomization |
   14.663 PARACHUTE Trial Participants deemed unsuitable by investigator |
   14.664 PARACHUTE Trial Participants randomized into groups |
   14.665 PARACHUTE Trial Participants randomized into groups for screened group |
   14.666 PARACHUTE Trial Participants randomized into groups with comparator |
   14.667 PARACHUTE Trial Participants randomized into groups with intervention |
   14.668 PARACHUTE Trial Participants that completed 30 day follow up |
   14.669 PARACHUTE Trial Participants that completed 30 day follow up with comparator |
   14.670 PARACHUTE Trial Participants that completed 30 day follow up with intervention |
   14.671 PARACHUTE Trial Participants that completed jump and 5 minute follow-up |
   14.672 PARACHUTE Trial Participants that completed jump and 5 minute follow-up with comparator |
   14.673 PARACHUTE Trial Participants that completed jump and 5 minute follow-up with intervention |
   14.674 PARACHUTE Trial Participants that declined randomization |
   14.675 PARACHUTE Trial Participants with no contact at 30 days |
   14.676 PARACHUTE Trial Participants with no contact at 30 days with comparator |
   14.677 PARACHUTE Trial Participants with no contact at 30 days with intervention |
   14.678 PARACHUTE Trial Results |
   14.679 Parachute use to prevent death and major trauma when jumping from aircraft: randomized controlled trial. |
   14.680 Parachute vs Empty Backpack in PARACHUTE Trial |
   14.681 Participant Flow Report for NCT03640312 |
   14.682 Participant Flow Report for QUARTET USA Trial |
   14.683 Participant Flow Variables List for PARACHUTE Trial |
   14.684 ParticipantFlow: 2018 Norwegian Cohort Included in Analysis |
   14.685 ParticipantFlow: 2018 Norwegian Cohort Medical Group Included in Analysis |
   14.686 ParticipantFlow: 2018 Norwegian Cohort Surgical Group Included in Analysis |
   14.687 ParticipantFlowEvidence: 2018 Norwegian Cohort Excluded from Analysis |
   14.688 ParticipantFlowMeasure: Dropout due to stopping intervention |
   14.689 ParticipantFlowMeasure: Exclusion from analysis |
   14.690 ParticipantFlowMeasure: Inclusion in analysis |
   14.691 Participants Excluded from PARACHUTE Study |
   14.692 Participants_in_Anticoagulation_for_COVID_19_Combined_ATTACC_ACTIV_4a_and_REMAP_CAP_RCT_hospitalized_not_critically_ill |
   14.693 Patients_who_are_hospitalized_for_COVID_19_and_who_are_not_critically_ill |
   14.694 Percentage of Participants With Potentially Related Adverse Events (NCT03640312) |
   14.695 Percentage of Participants With Potentially Related Adverse Events at 12 weeks for Candesartan in NCT03640312 |
   14.696 Percentage of Participants With Potentially Related Adverse Events at 12 weeks for QUARTET LDQT in NCT03640312 |
   14.697 Percentage of Participants With Potentially Related Adverse Events at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312 |
   14.698 Percentage of Participants With Serious Adverse Events (SAEs) (NCT03640312) |
   14.699 Percentage of Participants With Serious Adverse Events (SAEs) at 12 weeks for Candesartan in NCT03640312 |
   14.700 Percentage of Participants With Serious Adverse Events (SAEs) at 12 weeks for QUARTET LDQT in NCT03640312 |
   14.701 Percentage of Participants With Serious Adverse Events (SAEs) at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312 |
   14.702 Placebo |
   14.703 PlanDefinition for Recommendation: ADA Obesity Management Recommendation 8.16 |
   14.704 PlanDefinition for Recommendation: ADA Obesity Management Recommendation 8.17 |
   14.705 PreprintCitation: Nigella Sativa for COVID-19 OSF Preprint |
   14.706 Proportion of Patients With Adverse Event Free Hypertension Control (NCT03640312) |
   14.707 Proportion of Patients With Adverse Event Free Hypertension Control at 12 weeks for Candesartan in NCT03640312 |
   14.708 Proportion of Patients With Adverse Event Free Hypertension Control at 12 weeks for QUARTET LDQT in NCT03640312 |
   14.709 Proportion of Patients With Adverse Event Free Hypertension Control at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312 |
   14.710 Proportion of Patients With Hypertension Control (NCT03640312) |
   14.711 Proportion of Patients With Hypertension Control at 6 and 12 weeks - 12 weeks at (NCT03640312) |
   14.712 Proportion of Patients With Hypertension Control at 6 and 12 weeks - 12 weeks for Candesartan in NCT03640312 |
   14.713 Proportion of Patients With Hypertension Control at 6 and 12 weeks - 12 weeks for QUARTET LDQT in NCT03640312 |
   14.714 Proportion of Patients With Hypertension Control at 6 and 12 weeks - 6 weeks at (NCT03640312) |
   14.715 Proportion of Patients With Hypertension Control at 6 and 12 weeks - 6 weeks for Candesartan in NCT03640312 |
   14.716 Proportion of Patients With Hypertension Control at 6 and 12 weeks - 6 weeks for QUARTET LDQT in NCT03640312 |
   14.717 Proportion of Patients With Hypertension Control at 6 and 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312 |
   14.718 Quadpill once daily |
   14.719 QUARTET USA Trial Control Group |
   14.720 QUARTET USA Trial Quadpill group |
   14.721 randomized into groups for PARACHUTE Trial |
   14.722 Rate of Adverse Events of Special Interest (NCT03640312) |
   14.723 Rate of Adverse Events of Special Interest at 12 weeks for Candesartan in NCT03640312 |
   14.724 Rate of Adverse Events of Special Interest at 12 weeks for QUARTET LDQT in NCT03640312 |
   14.725 Rate of Adverse Events of Special Interest at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312 |
   14.726 Rate of Death or Major Traumatic Injury on Impact with comparator |
   14.727 Rate of Death or Major Traumatic Injury on Impact with intervention |
   14.728 Reasons for exclusion from QUARTET USA Trial |
   14.729 Recommendation Eligibility Criteria for Bariatric Surgery (ADA Recommendation 8.17) |
   14.730 Recommendation Justification Code System |
   14.731 Recommendation Rating: ADA Obesity Management Recommendation 8.16 |
   14.732 Recommendation: ADA Obesity Management Recommendation 8.16 |
   14.733 Recommendation: ADA Obesity Management Recommendation 8.16-adapted |
   14.734 Recommendation: ADA Obesity Management Recommendation 8.17 |
   14.735 RecommendationEligibilityCriteria: Eligibility Criteria for Bariatric Surgery (ADA Recommendation 8.16) |
   14.736 Remdesivir |
   14.737 Remdesivir IV 200 mg once then 100 mg once daily for 9 days |
   14.738 Results Section for NCT03640312 |
   14.739 Risk of Bias Assessment of Critically appraised summary of primary outcome of multi-platform RCT of anticoagulation for non-critically ill patients with COVID-19 |
   14.740 Risk of Bias Assessment of PARACHUTE trial |
   14.741 Risk Of Bias Type Value Set |
   14.742 Screened Group PARACHUTE Trial |
   14.743 Search Strategy for NMA_Diabetes |
   14.744 SearchResults: PubMed search for Wonder Woman |
   14.745 SearchStrategy: PubMed and Embase search for van Veldhuisen 2022 systematic review |
   14.746 SearchStrategy: PubMed search for Wonder Woman |
   14.747 Sex |
   14.748 Sex with comparator |
   14.749 Sex with intervention |
   14.750 SGLT2 inhibitors Group in Adults with type 2 diabetes |
   14.751 SoaPlanDefinition: Follow-up assessment 3 months after study start |
   14.752 SoftwareCitation: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter |
   14.753 Spanish or English Value Set |
   14.754 Standard care Group in Adults with type 2 diabetes with moderate CV risk |
   14.755 StudyCitation: 2022 Systematic Review of bariatric surgery mortality effect 35243488 |
   14.756 StudyEligibilityCriteria: Eligibility Criteria for DIBASY Trial |
   14.757 StudyEligibilityCriteria: Obese patients ≥ 18 years old |
   14.758 StudyEligibilityCriteria: Type 2 diabetes and elevated BMI in 2016 meta-analysis |
   14.759 StudyEligibilityCriteria_Eligibility_Criteria_for_Bariatric_Surgery_Randomized_Trial_Diabetes_Surgery_Study |
   14.760 StudyGroup: Diabetes Surgery Study Trial Enrollment Group |
   14.761 StudyGroup: Severely Obese Adults 2018 Norwegian Cohort |
   14.762 StudyGroup_DIBASY_Trial_Enrollment_Group |
   14.763 SummaryOfFindings: Bariatric Surgery Summary of Findings Example for GIN 2022 |
   14.764 SummaryOfFindings: GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk |
   14.765 SummaryOfFindings: SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes |
   14.766 SummaryOfNetEffect: Bariatric Surgery Summary of Net Effect Contributions Example for GIN 2022 |
   14.767 SystematicReviewEligibilityCriteria: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer |
   14.768 SystematicReviewExcludedStudies: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer |
   14.769 SystematicReviewIncludedStudies: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer |
   14.770 Systolic blood pressure at 12 weeks |
   14.771 Time to integration of results in a recommendation |
   14.772 VariableDefinition: Comparator |
   14.773 VariableDefinition: Condition(s) |
   14.774 VariableDefinition: Date of birth |
   14.775 VariableDefinition: Date of measurement |
   14.776 VariableDefinition: Gender |
   14.777 VariableDefinition: NTproBNP |
   14.778 VariableDefinition: Unit |
   14.779 Velocity |
   14.780 Velocity comparing intervention vs. comparator |
   14.781 Velocity for enrolled group |
   14.782 Velocity for non participant group |
   14.783 Velocity with comparator |
   14.784 Velocity with intervention |
   14.785 WebPageCitation: A HEvKA Update Summary |
   14.786 Weight |
   14.787 Weight with comparator |
   14.788 Weight with intervention |